WO2001062785A3 - Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie - Google Patents

Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie Download PDF

Info

Publication number
WO2001062785A3
WO2001062785A3 PCT/GB2001/000792 GB0100792W WO0162785A3 WO 2001062785 A3 WO2001062785 A3 WO 2001062785A3 GB 0100792 W GB0100792 W GB 0100792W WO 0162785 A3 WO0162785 A3 WO 0162785A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
treatment
spis
diagnosis
detectable
Prior art date
Application number
PCT/GB2001/000792
Other languages
English (en)
Other versions
WO2001062785A2 (fr
Inventor
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Jonathan Alexander Terrett
Kerry Louise Tyson
Original Assignee
Oxford Glycosciences Uk Ltd
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Jonathan Alexander Terrett
Kerry Louise Tyson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004415A external-priority patent/GB0004415D0/en
Application filed by Oxford Glycosciences Uk Ltd, Herath Mudiyanselage At Herath, Rajesh Bhikhu Parekh, Christian Rohlff, Jonathan Alexander Terrett, Kerry Louise Tyson filed Critical Oxford Glycosciences Uk Ltd
Priority to AU2001237543A priority Critical patent/AU2001237543A1/en
Priority to EP01909957A priority patent/EP1259607A2/fr
Publication of WO2001062785A2 publication Critical patent/WO2001062785A2/fr
Publication of WO2001062785A3 publication Critical patent/WO2001062785A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et compositions de dépistage, diagnostic et pronostic de la schizophrénie, de surveillance de l'efficacité du traitement de cette maladie, d'identification des patients les plus susceptibles de répondre à un traitement thérapeutique en particulier, et de mise au point de médicaments. L'invention concerne également des caractéristiques associées à la schizophrénie qui peuvent être détectées à l'aide d'une électrophorèse bidimensionnelle du liquide céphalo-rachidien, du sérum ou du plasma. L'invention concerne encore des isoformes de protéines associées à la schizophrénie, lesquelles peuvent être détectées dans le liquide céphalo-rachidien, le sérum ou le plasma, des préparations comprenant des isoformes isolées, des anticorps immunospécifiques de ces isoformes, ainsi que des kits comprenant ces substances.
PCT/GB2001/000792 2000-02-24 2001-02-23 Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie WO2001062785A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001237543A AU2001237543A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia
EP01909957A EP1259607A2 (fr) 2000-02-24 2001-02-23 Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004415A GB0004415D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of schizophrenia
GB0004415.6 2000-02-24
US75039500A 2000-12-28 2000-12-28
US09/750,395 2000-12-28

Publications (2)

Publication Number Publication Date
WO2001062785A2 WO2001062785A2 (fr) 2001-08-30
WO2001062785A3 true WO2001062785A3 (fr) 2002-01-31

Family

ID=26243725

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2001/000792 WO2001062785A2 (fr) 2000-02-24 2001-02-23 Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
PCT/GB2001/000783 WO2001063293A2 (fr) 2000-02-24 2001-02-23 Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000783 WO2001063293A2 (fr) 2000-02-24 2001-02-23 Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie

Country Status (3)

Country Link
EP (2) EP1259818A2 (fr)
AU (2) AU2001237543A1 (fr)
WO (2) WO2001062785A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1573024A4 (fr) 2001-04-10 2007-08-29 Agensys Inc Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
AU2002330215A1 (en) * 2001-10-03 2003-04-14 Oxford Glycosciences (Uk) Ltd. Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030100012A1 (en) * 2001-11-23 2003-05-29 George Jackowski Plasma protease C1 biopolymer markers predictive of alzheimers disease
CA2476765A1 (fr) 2002-02-21 2003-09-04 Quark Biotech, Inc. Methodes de prevention ou de traitement d'ischemies ou de lesions cerebrales
CN1300588C (zh) * 2005-02-28 2007-02-14 上海交通大学 用于精神分裂症诊断的血浆特异性蛋白获取方法及应用
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
EP2370088B1 (fr) * 2008-12-27 2016-08-24 Pawan Saharan Nanopeptides dérivés d'un colostrum mammalien pour infections virales et récurrentes à large spectre avec leur procédé d'isolement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039133A1 (fr) * 1996-04-08 1997-10-23 The Johns Hopkins University School Of Medicine Nouveau facteur de croissance des cellules neuronales
WO2001036626A2 (fr) * 1999-11-15 2001-05-25 Merck Patent Gmbh Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
AU4480997A (en) * 1996-09-13 1998-04-02 Mount Sinai School Of Medicine Of The City University Of New York, The Screening methods for compounds useful in the treatment of schizophrenia
AU6465798A (en) * 1997-03-14 1998-09-29 Neuromark Diagnosing neurologic disorders
US5939316A (en) * 1997-03-27 1999-08-17 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
EP1012300A1 (fr) * 1997-09-05 2000-06-28 Acorda Therapeutics Sulfotransferase hnk-1 et ses methodes d'utilisation
ATE447583T1 (de) * 1997-09-17 2009-11-15 Genentech Inc Polypeptide und dafür kodierende nukleinsäure
US6248527B1 (en) * 1998-10-21 2001-06-19 Millennium Pharmaceuticals, Inc. Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU7508100A (en) * 1999-10-04 2001-05-10 Jens Andersen Human seizure related proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039133A1 (fr) * 1996-04-08 1997-10-23 The Johns Hopkins University School Of Medicine Nouveau facteur de croissance des cellules neuronales
WO2001036626A2 (fr) * 1999-11-15 2001-05-25 Merck Patent Gmbh Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMHUM1 EMBL Heidelberg, Germany; 10 October 1997 (1997-10-10), LLOYD D: "Pentraxin receptor", XP002172003 *
DODDS ET AL: "Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 34, 22 August 1997 (1997-08-22), pages 21488 - 21494, XP002140646, ISSN: 0021-9258 *
REID M S ET AL: "APEXIN, AN ACROSOMAL PENTAXIN", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 269, no. 51, 1994, pages 32615 - 32620, XP000910119, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2001063293A2 (fr) 2001-08-30
AU2001233954A1 (en) 2001-09-03
EP1259607A2 (fr) 2002-11-27
WO2001063293A3 (fr) 2002-04-11
WO2001063293A8 (fr) 2001-10-18
AU2001237543A1 (en) 2001-09-03
WO2001062785A2 (fr) 2001-08-30
EP1259818A2 (fr) 2002-11-27

Similar Documents

Publication Publication Date Title
WO2002059604A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques
WO2002054081A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse renale
WO2001075454A3 (fr) Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment
DE69933661D1 (de) Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
WO2003028543A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees comprenant le diagnostic et le traitement de la maladie d'alzheimer
WO2002082075A3 (fr) Procede de depistage de maladies dementielles chroniques, et peptides et reactifs de depistage correspondants
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2001013117A3 (fr) Proteines et genes destines au diagnostic et au traitement du cancer du sein et leur utilisation
WO2005040421A3 (fr) Marqueurs de pronostic et de diagnostic des troubles de proliferation cellulaire dans les tissus mammaires
WO2002046767A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
MXPA02008239A (es) Gen humano de la esquizofrenia.
WO2001062785A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
EP1297147B8 (fr) Compositions pour le diagnostic et le traitement de l'infection du virus de l'herpes
WO2001063294A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de maladies affectives bipolaires (bad) et de depressions unipolaires
WO2001062784A3 (fr) Proteines
EP1283272A3 (fr) Méthodes et moyens d'évaluation d'une thérapie à base des inhibiteurs de l'enveloppe du VIH
WO2001069261A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
WO2000022122A3 (fr) Genes, proteines et marqueurs bialleliques lies a une maladie du systeme nerveux central
WO2004051269A3 (fr) Proteine de replication
WO2003048734A3 (fr) Detection d'arn de metalloproteinase matricielle dans du plasma et du serum
ATE255229T1 (de) Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
WO2002054080A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire
WO2001013118A3 (fr) Procedes et compositions permettant le diagnostic de l'hepatome
WO2002046768A3 (fr) Protéines, gènes, et leur utilisation pour le diagnostic et le traitement de l'asthme chronique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001909957

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001909957

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001909957

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP